Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback